Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CHRNG | P07510 | 1/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CHRND | Q07001 | 1/20 | 0.51 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30847846 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 | |
| Cyanide SCHEMBL27676360 | 0.94 | CHRNB2 (0.49) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL21354925 | 0.91 | CHRNB2 (0.54) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL1962531 | 0.91 | KMT2A (0.51) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL28849502 | 0.90 | KMT2A (0.54) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL2081673 | 0.89 | CHRNB2 (0.64) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL25330905 | 0.86 | CHRNB2 (0.49) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL2408691 | 0.85 | CHRNB2 (0.48) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL9159120 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL9159113 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA3CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104911650-A | Novel electroplating solution for gallium plating | LIANG SHENGGUANG | 2015-09-16 | — | — | CN | claimed |
| WO-2025111414-A1 | TRPM3-MODULATING BENZOFURAN DERIVATIVES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-05-30 | — | — | WO | disclosed |
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-114901660-B | Substituted bicyclic compounds useful as T cell activators | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-114630822-B | Biaryl dihydroorotate acid dehydrogenase inhibitors | 詹森生物科技公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2237669-A2 | CHEMICAL COMPOUNDS | Syngenta Limited (GB) | 2010-10-13 | — | — | EP | disclosed |
| EP-2121613-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009081112-A2 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| WO-2008094992-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CHRNB2 4583/4885CHRNA7 4609/4885CHRNA3 4489/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CHRNB2 4583/4885CHRNA7 4609/4885CHRNA3 4489/4885 |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | DDT, PNPO, CBR3 | CHRNB2 4122/4885CHRNA7 4045/4885CHRNA3 4093/4885 |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | CHRNB2 4864/4885CHRNA7 4851/4885CHRNA3 4793/4885 |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | CHRNA10, ATXN10, SCN10A | CHRNB2 65/4885CHRNA7 25/4885CHRNA3 24/4885 |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | CHRNB2 2832/4885CHRNA7 1836/4885CHRNA3 1603/4885 |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | CHRNB2 4772/4885CHRNA7 4780/4885CHRNA3 4736/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CHRNB2 4583/4885CHRNA7 4609/4885CHRNA3 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.